Loading
A small Dana-Farber study of what the Galleri test finds, and misses, when it is used repeatedly in people who have symptoms.
DISCOVER (NCT07390643) is a single-arm interventional study sponsored by Dana-Farber Cancer Institute. Its primary outcomes are the type, incidence and stage of cancers found by Galleri and of cancers it did not detect.
The registry record, read on 29 October 2026, gives its status as not yet recruiting, with an estimated 100 participants, a planned start in July 2026 and primary completion expected on 31 January 2027.
Shares GRAIL, Galleri, Dana-Farber Brigham Cancer Center, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Dana-Farber Brigham Cancer Center, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/